euragen® gel versus placebo in the relief of neuropathic foot pai

Completed

• Conditions: Peripheral neuropathy; Nervous System Diseases; Other polyneuropathies

• Registration Number: ISRCTN37736407
• Lead Sponsor: Origin BioMed, Inc. (Canada)

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2009-11-09
• Last Update Posted: 13 January 2015

Recruitment & Eligibility

• Status: Completed
• Sex: All
• Target Recruitment: 60

Inclusion Criteria

1. Male and female aged over 21 years
2. Diagnosed with neuropathic pain more 3 months
3. Pain level between 5 - 9 on a 0 - 10 visual pain scale
4. Does not have mental and communication impairments

Exclusion Criteria

1. Pregnant
2. Have other types of pain
3. Skin condition
4. Central nerve impairments

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
evel of pain on a 0 - 10 visual pain scale, measured 30 minutes before and after the application of of the treatment, and every hour thereafter for 8 hours.

Secondary Outcome Measures

Name	Time	Method
Duration of pain reduction, measured on a 0 - 10 visual pain scale which will be used every hour on the hour for up to 8 hours.